<DOC>
	<DOCNO>NCT00960284</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine hydrochloride , cisplatin , epirubicin hydrochloride , fluorouracil , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . It yet know whether gemcitabine hydrochloride effective give alone together combination chemotherapy radiation therapy treat patient pancreatic cancer . PURPOSE : This randomized phase II/III trial study gemcitabine hydrochloride see well work give alone together combination chemotherapy radiation therapy treat patient stage IB , stage II , stage III pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine Combination Chemotherapy Followed Chemoradiation Stage IB , II , III Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess 1-year progression-free survival patient stage IB , II , III adenocarcinoma pancreas treat adjuvant therapy comprise gemcitabine v without cisplatin , epirubicin hydrochloride , fluorouracil follow chemoradiotherapy fluorouracil capecitabine . ( Phase II ) - Compare 2-year overall survival patient treat regimen . ( Phase III ) Secondary - Assess feasibility toxicity regimens patient . - Assess impact regimens quality life patient . - Assess pattern relapse patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord participate center radical surgery . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride IV 1 hour day 1 , 8 , 15 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . - Arm II : Patients receive cisplatin IV 1 hour epirubicin hydrochloride IV day 1 gemcitabine hydrochloride IV 1 hour day 1 8 . Patients also receive fluorouracil IV continuously begin day 1 oral capecitabine . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . Beginning 2-4 week completion chemotherapy , patient arm undergo radiotherapy 5 day week 6 week . Patients also receive concurrent fluorouracil IV continuously oral capecitabine radiotherapy . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas Stage IBIII disease Has undergone surgery radical intent ( R0 R1 ) within past 2 month PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % ( 90100 % patient 7175 year age ) WBC ≥ 3,500/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Creatinine ≤ 1.5 mg/dL Bilirubin ≤ 2 mg/dL SGOT SGPT ≤ 2 time upper limit normal Not pregnant nursing No malignancy within past 5 year except surgically treat carcinoma situ cervix basal cell squamous cell carcinoma skin No psychological , familial , sociological , geographical condition would potentially hinder study compliance followup schedule PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy radiotherapy pancreatic adenocarcinoma No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>stage IB pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>